Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MIUDELLA vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MIUDELLA (everolimus) is an m TOR inhibitor that binds to the FKBP-12 protein to form a complex that inhibits the m TOR kinase activity, thereby reducing cell proliferation, angiogenesis, and glucose uptake.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Advanced HR+, HER2- breast cancer in postmenopausal women (with exemestane after failure of letrozole or anastrozole),Progressive neuroendocrine tumors of pancreatic origin (PNET) in adults with unresectable, locally advanced or metastatic disease,Advanced renal cell carcinoma after failure of sunitinib or sorafenib,Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) in patients requiring therapeutic intervention but not candidates for curative surgery,Renal angiomyolipoma associated with TSC, not requiring immediate surgery,TSC-associated partial-onset seizures
Prevention of pregnancy
Intravenous: 1.5 mg/kg every 12 hours for 14 days.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal elimination half-life is 18-24 hours in healthy adults; prolonged in renal impairment (up to 40 hours in severe cases).
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Primarily metabolized by CYP3A4; also a substrate of P-glycoprotein (P-gp). Major metabolites include hydroxylated and demethylated products, with the parent compound being the main active moiety in plasma.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Primarily renal excretion of unchanged drug (85-90%); biliary/fecal elimination accounts for 5-10%.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Approximately 92% bound to serum albumin and alpha-1-acid glycoprotein.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive tissue distribution.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral bioavailability is 65-80% (first-pass metabolism); intravenous is 100%.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
GFR 30-89 m L/min: 1.5 mg/kg every 24 hours; GFR <30 m L/min: 1.5 mg/kg every 48 hours.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Child-Pugh Class B: 1 mg/kg every 12 hours; Child-Pugh Class C: 0.5 mg/kg every 12 hours.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Children (≥2 years): 1.5 mg/kg intravenously every 12 hours for 14 days; maximum 2 g/day.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
No specific dose adjustment; monitor renal function and reduce dose if GFR <90 m L/min.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
None.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Non-infectious pneumonitis: Monitor for respiratory symptoms; manage with dose reduction or interruption.,Infections: Increased risk of bacterial, viral, fungal, and protozoal infections; monitor for signs and symptoms.,Oral ulceration: Manage with topical treatments, dose reduction, or interruption.,Renal failure: Monitor renal function; dose adjustment may be needed.,Metabolic effects: Monitor blood glucose and lipids; hyperglycemia, hyperlipidemia, and hypertriglyceridemia may occur.,Myelosuppression: Monitor blood counts; anemia, leukopenia, thrombocytopenia, and lymphopenia can occur.,Immunizations: Avoid live vaccines during treatment.,Embryo-fetal toxicity: Can cause fetal harm; advise women of reproductive potential of effective contraception.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Severe hypersensitivity to everolimus, other rapamycin derivatives, or any component of the formulation.
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
Avoid grapefruit and grapefruit juice, as they may inhibit CYP3A4 metabolism and increase MIUDELLA plasma concentrations. No other specific food restrictions; however, limit caffeine intake as it may exacerbate side effects like insomnia or anxiety.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
Pregnancy Category X. First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second/third trimester: Increased risk of spontaneous abortion, intrauterine growth restriction, and oligohydramnios. Contraindicated in pregnancy.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Contraindicated due to potential toxicity; no human M/P ratio available. Excretion into breast milk is likely based on animal studies; discontinue nursing or drug.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Not applicable; contraindicated in pregnancy. No dose adjustment can mitigate teratogenic risk.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
MIUDELLA (fictitious drug) is a selective serotonin reuptake inhibitor (SSRI) indicated for major depressive disorder. Onset of therapeutic effect may require 2-4 weeks; assess suicide risk in young adults during initial therapy. Use with caution in patients with hepatic impairment (reduce dose by 50% for Child-Pugh class B/C). Avoid abrupt discontinuation to prevent withdrawal syndrome (taper over 2-4 weeks).
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take MIUDELLA exactly as prescribed at the same time each day, with or without food.,Do not stop taking MIUDELLA suddenly; a gradual dose reduction is required to avoid withdrawal symptoms.,Report worsening depression or suicidal thoughts immediately, especially during the first few months of treatment.,Avoid alcohol consumption while on MIUDELLA as it may increase drowsiness and potentiate central nervous system effects.,Contact your healthcare provider if you experience a rash, hives, or swelling, as these may indicate an allergic reaction.,Inform all healthcare providers that you are taking MIUDELLA, including before any surgery or dental procedure.,Store MIUDELLA at room temperature away from moisture and heat, and keep out of reach of children.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MIUDELLA vs ALYACEN 7/7/7, answered by our medical review team.
MIUDELLA is a Oral Contraceptive that works by MIUDELLA (everolimus) is an m TOR inhibitor that binds to the FKBP-12 protein to form a complex that inhibits the m TOR kinase activity, thereby reducing cell proliferation, angiogenesis, and glucose uptake.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MIUDELLA and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MIUDELLA is: Intravenous: 1.5 mg/kg every 12 hours for 14 days.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MIUDELLA and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MIUDELLA is classified as Category C. Pregnancy Category X. First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second/third trimester. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.